AFAmaury Ernesto Fernández‐Montalván
Amaury Ernesto Fernández‐Montalván
*This is an algorithmically generated author record based on publicly available information.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Amaury Ernesto Fernández‐Montalván has a total of 289 co-authors. Here are the top co-authors by number of shared publications:
Simon J. Holton
28 shared publicationsDominik Mumberg
27 shared publicationsFranz von Nussbaum
26 shared publicationsHans Briem
25 shared publicationsKarl Ziegelbauer
25 shared publicationsMichael Brands
25 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Elsevier in SLAS Discovery
- Vol. 43, 100327
A high throughput screening platform for label-free identification and characterization of GPCR ligands using impedance-based real-time cellular analysis
- 29 July 2026
- Published by Elsevier in SLAS Discovery
- Vol. 43, 100327
Open AccessA high throughput screening platform for label-free identification and characterization of GPCR ligands using impedance-based real-time cellular analysis
- Open Access
- 13 March 2026
- Published by Elsevier in SLAS Discovery
- Vol. 40, 100302
A versatile acoustic droplet ejection mass spectrometry platform enables drug discovery for the solute carrier (SLC) target family
- 13 March 2026
- Published by Elsevier in SLAS Discovery
- Vol. 40, 100302
Open AccessA versatile acoustic droplet ejection mass spectrometry platform enables drug discovery for the solute carrier (SLC) target family
- Open Access
- 8 April 2023
- Published by Elsevier in SLAS Discovery
- Vol. 28 (5) , 240-246
Label-free high-throughput screening via acoustic ejection mass spectrometry put into practice
- 8 April 2023
- Published by Elsevier in SLAS Discovery
- Vol. 28 (5) , 240-246
Open AccessLabel-free high-throughput screening via acoustic ejection mass spectrometry put into practice
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
Exposure data from xenograft studies
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
Exposure data from xenograft studies
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
Anti-proliferative cell line profile of BAY 1816032
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
Anti-proliferative cell line profile of BAY 1816032
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends and Methods from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
Supplementary Figure Legends, Methods and References
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends and Methods from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
Supplementary Figure Legends, Methods and References
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
Anti-proliferative cell line profile of BAY 1816032
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
Anti-proliferative cell line profile of BAY 1816032